EuroBiotech—More articles of note

(NS Newsflash/CC BY 2.0)

> E-Therapeutics (ETX) struck agreements with Intellegens and Biorelate to access artificial intelligence tools. Pilot studies suggest the tools complement ETX’s computational drug discovery technology. Statement

> ValiRx presented an analysis of data from a phase 2 trial of cancer candidate VAL401. Release 

> Avacta and Glythera entered into a licensing agreement. The signing of the deal follows an initial study to evaluate the use of Avacta's Affimer technology with Glythera's conjugation chemistry. Statement

> British trade group The BioIndustry Association secured clearance to intervene in a Supreme Court patent case. The BIA is concerned the court’s ruling could affect how much data and evidence companies need to patent inventions. Release

> Transgene’s China joint venture dosed the first hepatitis B patient in a phase 1 trial. Statement

> TxCell snagged a government loan to support preclinical development of its lead CAR-Treg program. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.